ClinicalTrials.gg
CompletedNCT04186442Updated Apr 15, 2022

Evaluate the Safety and Efficacy of Botulax® Versus Botox® in Patient With Overactive Bladder

A Phase 1 interventional study of Botulinum toxin type A injection and Botulinum Toxin Type A Injection [Botox] in Overactive Bladder, sponsored by Hugel. Completed at 1 site in Korea, Republic of. Open to female participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2022-04-15.

Sponsored by Hugel · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
19 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing botulinum toxin type A in Urinary Bladder, Overactive — 3 open to participants now, 5 under way, 1 of them phase 3. botulinum toxin type A · Urinary Bladder, Overactive.

Enrollment
33rd of 44
38 · median 84
Started
2020
the only one that year
Phase 1
3 of 44
none open now
Registered
37th of 44
by date

Among the 44 studies testing botulinum toxin type A in Urinary Bladder, Overactive, this one is the 33rd largest by enrollment, is the only one that started in 2020, is one of 3 in phase 1, and was the 37th registered.

Urinary Bladder, Overactive

859 studies on the registry are indexed under Urinary Bladder, Overactive; 127 are open to participants now.

Browse Urinary Bladder, Overactive studies →

Open to participants now

3 of the 44 studies testing botulinum toxin type A in Urinary Bladder, Overactive are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About botulinum toxin type A

botulinum toxin type A: first FDA approval 1991 (BOTOX COSMETIC), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 74 Urinary Bladder, Overactive studies recruiting now, 44 (59%) set no upper age limit and 16 (22%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.

This study: 19 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing botulinum toxin type A in Urinary Bladder, Overactive, or all of them as a file.
02

Study summary

To determine the efficacy and safety of Botulax® in treatment of Overactive Bladder

Read the detailed description

A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase I Clinical Trial to Compare the Safety and Efficacy of Botulax® versus Botox® in Patient with Overactive Bladder

03

Conditions studied

  • Overactive Bladder
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female at the age of 19 or older
  2. Subjects who agree to participate in the clinical study and voluntarily sign the written form
  3. Subjects with idiopathic overactive bladder who meets the following conditions:

    1. Subjects with persistent overactive bladder symptoms for the last 12 weeks
    2. Subjects who are not properly controlled by the administration of anticholinergic agents for 4 weeks or more or who are difficult to treat due to adverse reactions
    3. Subjects with urinary incontinence, urgency, and urinary frequency symptoms
  4. Subjects who are willing to perform clean intermittent catheterization (CIC), if needed

Exclusion criteria

Exclusion Criteria:

Subjects who are eligible for any of the following conditions may not participate in this study:

  1. Subjects with the following comorbidities:

    1. Subjects with peripheral motor neuron disease (eg. amyotrophic lateral sclerosis, motor neuropathy) or systemic neuromuscular junction disorders (eg. myasthenia gravis, Lambert-Eaton syndrome)
    2. Overactive bladder patients due to neurological factors (eg stroke, spinal cord disease, Parkinson's disease, etc.)
    3. Subjects with stress incontinence
    4. Subjects with Urinary Tract Infections*

      * Culture showing ≥10\^5 colony-forming units (CFU)/mL and leukocytes ≥5 high power field (HPF)

    5. Patients with acute urinary retention, or with a history or accompanying diseases that can cause urinary retention (urolithiasis, acute cystitis, foreign body in the bladder, bladder flow, etc.)
    6. Uncontrolled diabetes patients who meet one or more of the following criteria:

      • ≥ 9% at screening
      • Patients with over 10 years of diabetes
      • Have diabetic chronic complications (eg diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, etc.)
      • Patients taking a drug that causes glycosuria (sodium-glucose co-transporter 2 inhibitor, SGLT2 inhibitor)
  2. Those who have had lower urinary tract surgery within 24 weeks before screening
  3. Those who received botulinum toxin due to urinary system disease within 24 weeks before screening
  4. Those who have been administered botulinum toxin type A within 12 weeks prior to screening or botulinum toxin type B within 16 weeks of treatment, or planned during the clinical trials
  5. Those who have received or plan to receive oral medications for overactive bladder including anticholinergic drugs within 1 week prior to randomization
  6. Those who received antiplatelet and anticoagulants within 1 week prior to randomization
  7. Subjects with a history of reactions to any of the components of the product
  8. Women of who are planning to become pregnant during the clinical trials or are not using an appropriate method of
  9. Those who participated in another clinical trial within 12 weeks prior to screening and received investigational product/medical device/medical procedure
  10. Those who are sensitive to cephalosporin or penicillin antibiotics
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    Botulinum toxin type A (Botulax®)

    Drug: Botulinum toxin type A injection

  • Active comparator
    Botulinum toxin type A (Botox®)

    Drug: Botulinum Toxin Type A Injection [Botox]

Interventions

06

What researchers measure

Primary outcomes

  1. Adverse event incidence rates

    To assess severity and frequency of reported TEAE (treatment-emergent adverse event), ADR (adverse drug reaction), and SAE (serious adverse event) after investigational product injection

    Time frame: 12 weeks (during the clinical trial)

Secondary outcomes

  1. Urinary incontinence rate

    The change in the average number of Urinary incontinence per day at 2, 6 and 12 weeks from baseline

    Time frame: Baseline to Week 2, Week 6, Week 12

  2. Voiding frequency rate

    The change in the average number of voiding frequency per day at 2, 6 and 12 weeks from baseline

    Time frame: Baseline to Week 2, Week 6, Week 12

  3. Urinary urgency rate

    The change in the average number of urinary urgency (Urgency Rating Scale; URS≥2)per day at 2, 6 and 12 weeks from baseline

    Time frame: Baseline to Week 2, Week 6, Week 12

07

Study locations

1 site
  • Hugel
    Seoul, Korea 06162, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2020 to primary completion in Apr 2021, 11 months.

Of 20 industry-sponsored phase 1 interventional studies under Urinary Bladder, Overactive, half reached primary completion within 6 months of starting (the median); a quarter within 4 and three quarters within 11. This study's 11 months is above that.

Counting every sponsor, half of 30 studies reached it within 9 months; a quarter within 4 and three quarters within 22.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2019
First posted
Dec 4, 2019
StartActual
May 12, 2020
Primary completionActual
Apr 26, 2021
CompletionActual
Oct 26, 2021
Last update
Apr 15, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04186442
Lead sponsor
Hugel
Responsible party
Sponsor
First posted
Dec 4, 2019
Start date
May 12, 2020
Primary completion
Apr 26, 2021
Completion
Oct 26, 2021
Last update
Apr 15, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Botulinum toxin type A

Start the discussion